Tarsus Pharmaceuticals: Engaging Investors at Key Conferences

Tarsus Pharmaceuticals: Engaging Investors at Key Conferences
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), based in Irvine, California, is gearing up for an exciting series of investor conferences that promise to highlight the company's ongoing efforts and future potential. Through these events, Tarsus aims to connect with the investment community and share its vision for the future of healthcare.
Scheduled Conferences Overview
The first event on the agenda is the Bank of America Securities 2025 Health Care Conference, scheduled for Tuesday, May 13. During this conference, Tarsus management will present at 3:40 p.m. PT / 6:40 p.m. ET. This platform offers a valuable opportunity for the company to showcase its innovative initiatives and foster meaningful discussions with investors.
H.C. Wainwright & Co. Conference
Subsequently, Tarsus will participate in the H.C. Wainwright & Co. 3rd Annual BioConnect Nasdaq Investor Conference on May 20. The representation at this conference will begin at 12:00 p.m. PT / 3:00 p.m. ET. This event underscores Tarsus's strong commitment to engaging with the investment community and addressing shareholder interest.
Stifel Virtual Ophthalmology Forum
On May 27, Tarsus will also take part in the Stifel Virtual Ophthalmology Forum at 7:30 a.m. PT / 10:30 a.m. ET. This forum specifically focuses on advancing ophthalmology, aligning well with Tarsus's core mission in the field of eye care.
Accessing Live Webcasts
For those interested in following these events, live webcasts and additional information will be readily available on the Tarsus website. The company will ensure that replays of the presentations are accessible within 48 hours, making it easy for investors to catch up on the insights shared during these critical discussions.
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc. is dedicated to transforming patient care through innovative and scientifically-backed treatments, starting with a strong focus on eye care. The company is advancing its product pipeline to tackle significant health conditions that currently lack effective treatment options.
Among its notable achievements, Tarsus has received FDA approval for XDEMVY (lotilaner ophthalmic solution) 0.25%, which is utilized for treating Demodex blepharitis. Additionally, the company is making strides with its R&D efforts on TP-04, which aims to offer potential solutions for Ocular Rosacea, and TP-05, an oral tablet designed for Lyme disease prevention. Tarsus's commitment to addressing urgent medical needs underscores its position as a forward-thinking leader in the healthcare sector.
Connect with Tarsus Pharmaceuticals
For any media inquiries, Adrienne Kemp serves as the Senior Director of Corporate Communications and can be reached at (949) 922-0801. Investors looking to connect can reach David Nakasone, the Head of Investor Relations, at (949) 620-3223. It's easy to see that Tarsus Pharmaceuticals values transparency and open communication with all stakeholders.
Frequently Asked Questions
What conferences is Tarsus attending?
Tarsus will participate in the Bank of America Securities Health Care Conference, H.C. Wainwright BioConnect Conference, and the Stifel Virtual Ophthalmology Forum.
When will Tarsus present at these conferences?
Tarsus's presentations are scheduled for May 13, May 20, and May 27, respectively.
How can I watch Tarsus's presentations?
Live webcasts of the presentations will be available on the Tarsus website, along with replays within 48 hours after the events.
What is Tarsus's focus area?
Tarsus focuses on advancing treatment for conditions primarily in the eye care field, with ongoing research in infections like Lyme disease.
Who can I contact for media inquiries at Tarsus?
Adrienne Kemp is the main contact for media inquiries at Tarsus Pharmaceuticals, available at (949) 922-0801.
About The Author
Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.